Amylin Pharmaceuticals

Amylin Pharmaceuticals Reviews

87 Reviews
87 Reviews
Rating Trends

Recommend to a friend
Approve of CEO
Amylin Pharmaceuticals President, CEO, and Director Dan Bradbury
Dan Bradbury
62 Ratings

    Innovation and improving patients lives

    Former Employee - Director in San Diego, CA
    Former Employee - Director in San Diego, CA

    I worked at Amylin Pharmaceuticals


    Good work-life balance, management support of career development and promotions. Generous options and bonus packages. I would recommend this place to others.


    Not too many cons that I can think was purchased by BMS and AZ in the last two years. I believe the San Diego site is going to be shut down.

    Negative Outlook
    Approves of CEO

Amylin Pharmaceuticals Interviews

Updated Sep 20, 2014
Updated Sep 20, 2014

Interview Experience

Interview Experience


Getting an Interview

Getting an Interview


Interview Difficulty


Interview Difficulty




    Diabetes Sales Specialist Interview

    Anonymous Employee in Jersey City, NJ
    Anonymous Employee in Jersey City, NJ
    Application Details

    I applied through a recruiter. The process took 4 daysinterviewed at Amylin Pharmaceuticals.

    Interview Details

    Contacted by recruiter to do a multi-person interview at a Hyatt hotel. Was basically a cattle call type set-up with tons of people being shifted to HR, marketing and management in different areas of the hotel. Very unorganized and highly unprofessional. Final IV with manager was a sad joke.

    Interview Questions
    • "If I gave you this pencil, do you think you could close for the business and get me to buy it?"   Answer Question
    No Offer
    Negative Experience
    Average Interview

Amylin Pharmaceuticals Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Headquarters San Diego, CA
Size 1000 to 5000 Employees
Acquired By Bristol-Myers Squibb
Founded 1987
Type Subsidiary or Business Segment
Industry Biotech & Pharmaceuticals
Revenue $100 to $500 million (USD) per year

Amylin Pharmaceuticals helps diabetics gain the upper hand in their battle with the disease. The company makes and markets injectable diabetes drugs Byetta and Symlin, which are approved as adjunct therapies to other diabetes treatments such as metformin and insulin. Byetta is also approved as a stand-alone diabetes therapy. Amylin gained FDA approval for Bydureon, a once-weekly version of Byetta, in 2012, and it is developing additional drugs for metabolic conditions. The company's US sales force markets its products to patients and physicians; development partner Eli... More

Work at Amylin Pharmaceuticals? Share Your Experiences

Amylin Pharmaceuticals

Click to Rate